Search

Your search keyword '"Piersma, D."' showing total 4 results
Start Over Author "Piersma, D." Publisher wiley-blackwell
4 results on '"Piersma, D."'

1. Seasonal variation of anti-PD-1 outcome in melanoma-Results from a Dutch patient cohort

Author

Cancer, MS Medische Oncologie, Infection & Immunity, Borgers, J S W, Burgers, F H, Schina, A, Van Not, O J, van den Eertwegh, A J M, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Boer, A M Stevense-den, van der Veldt, A A M, Vreugdenhil, G, Boers-Sonderen, M J, Wouters, M W J M, Suijkerbuijk, K P M, van Thienen, J V, Haanen, J B A G, Cancer, MS Medische Oncologie, Infection & Immunity, Borgers, J S W, Burgers, F H, Schina, A, Van Not, O J, van den Eertwegh, A J M, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Boer, A M Stevense-den, van der Veldt, A A M, Vreugdenhil, G, Boers-Sonderen, M J, Wouters, M W J M, Suijkerbuijk, K P M, van Thienen, J V, and Haanen, J B A G

Published
2024

2. Seasonal variation of anti‐PD‐1 outcome in melanoma—Results from a Dutch patient cohort.

Author

Borgers, J. S. W., Burgers, F. H., Schina, A., Van Not, O. J., van den Eertwegh, A. J. M., Blank, C. U., Aarts, M. J. B., van den Berkmortel, F. W. P. J., de Groot, J. W. B., Hospers, G. A. P., Kapiteijn, E., Piersma, D., van Rijn, R. S., Boer, A. M. Stevense‐den, van der Veldt, A. A. M., Vreugdenhil, G., Boers‐Sonderen, M. J., Wouters, M. W. J. M., Suijkerbuijk, K. P. M., and van Thienen, J. V.

Subjects
MELANOMA, SEASONS, OVERALL survival, COUNTRIES, SURVIVAL rate, ENVIRONMENTAL exposure, SEASONAL variations of diseases
Abstract

Despite the improved survival rates of patients with advanced stage melanoma since the introduction of ICIs, many patients do not have (long‐term) benefit from these treatments. There is evidence that the exposome, an accumulation of host‐extrinsic factors including environmental influences, could impact ICI response. Recently, a survival benefit was observed in patients with BRAF wild‐type melanoma living in Denmark who initiated immunotherapy in summer as compared to winter. As the Netherlands lies in close geographical proximity to Denmark and has comparable seasonal differences, a Dutch validation cohort was established using data from our nationwide melanoma registry. In this study, we did not observe a similar seasonal difference in overall survival and are therefore unable to confirm the Danish findings. Validation of either the Dutch or Danish findings in (combined) patient cohorts from other countries would be necessary to determine whether this host‐extrinsic factor influences the response to ICI‐treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Survival of stage IV melanoma in Belgium and the Netherlands

Author

MS Medische Oncologie, Infection & Immunity, Cancer, Anatomie, MS MOD, MS KNO, Suijkerbuijk, K. P.M., Haanen, J. B.A.G., Boers-Sonderen, M. J., Hospers, G. A.P., Blank, C. U., van den Berkmortel, F. W.P.J., de Groot, J. W.B., Piersma, D., Aarts, M. J.B., van Rijn, R. S., Vreugdenhil, G., Westgeest, H. M., Kapiteijn, E., van der Veldt, A. A.M., van den Eertwegh, A. J.M., MS Medische Oncologie, Infection & Immunity, Cancer, Anatomie, MS MOD, MS KNO, Suijkerbuijk, K. P.M., Haanen, J. B.A.G., Boers-Sonderen, M. J., Hospers, G. A.P., Blank, C. U., van den Berkmortel, F. W.P.J., de Groot, J. W.B., Piersma, D., Aarts, M. J.B., van Rijn, R. S., Vreugdenhil, G., Westgeest, H. M., Kapiteijn, E., van der Veldt, A. A.M., and van den Eertwegh, A. J.M.

Published
2022

4. Survival of stage IV melanoma in Belgium and the Netherlands.

Author

Suijkerbuijk, K.P.M., Haanen, J.B.A.G., Boers‐Sonderen, M.J., Hospers, G.A.P., Blank, C.U., van den Berkmortel, F.W.P.J., de Groot, J.W.B., Piersma, D., Aarts, M.J.B., van Rijn, R.S., Vreugdenhil, G., Westgeest, H.M., Kapiteijn, E., van der Veldt, A.A.M., and van den Eertwegh, A.J.M.

Subjects
MELANOMA, RESEARCH grants, TRAVEL costs
Abstract

Dr Aarts has advisory board / consultancy honoraria from Amgen, Bristol Myers Squibb, Novartis, MSD-Merck, Merck-Pfizer, Pierre Fabre, Sanofi, Astellas, Bayer. Prof vd Eertwegh has advisory relationships with Amgen, Bristol Myers Squibb, Roche, Novartis, MSD, Pierre Fabre, Sanofi, Pfizer, Ipsen, Merck and has received research study grants not related to this paper from Sanofi, Roche, Bristol Myers Squibb, Idera and TEVA and has received travel expenses from MSD Oncology, Roche, Pfizer and Sanofi and has received speaker honoraria from BMS and Novartis. Dr Suijkerbuijk has advisory relationships with Bristol Myers Squibb, Novartis, MSD, Pierre Fabre, Abbvie and received honoraria from Novartis, MSD and Roche. [Extracted from the article]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results